GlaxoSmithKline (GSK) and Theravance have announced the regulatory submissions for furoate FF/vilanterol VI (FF/VI) to treat chronic obstructive pulmonary disease (COPD) in the US and Europe. The companies also announced regulatory ...
AstraZeneca and Ardea Biosciences have entered into a definitive merger agreement, under which AstraZeneca will acquire Ardea for $1.26bn including a product lesinurad in Phase III development for gout. As per the agreement, AstraZeneca ...
Tags: AstraZeneca, Ardea, merger agreement, gout